Combining tumor response and personalized risk assessment: potential for adaptation of concurrent chemotherapy in locoregionally advanced nasopharyngeal carcinoma in the intensity-modulated radiotherapy era

Nasopharyngeal carcinoma (NPC) is rare worldwide but highly prevalent in southern China [1]. Roughly 70% of newly diagnosed cases present with locoregionally advanced NPC (LANPC) [2], whose management remains a challenge as treatment failures occur in nearly 30% of them [3,4]. Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) is currently widely recommended for LANPC due to its high efficacy and acceptable tolerance [5 –7].

Source: Radiotherapy and Oncology - October 6, 2020 Category: Radiology Authors: Wei-Jie Luo, Wen-Qing Zou, Shao-Bo Liang, Lei Chen, Guan-Qun Zhou, Hao Peng, Wen-Fei Li, Xu Liu, Ying Sun, Ai-Hua Lin, Jun Ma, Yan-Ping Mao Tags: Original Article Source Type: research